CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ | $4.995 -3.94% -5.91% 19K

(0.0% 1d) (1.2% 1m) (-20.4% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-44.98% volume)
Earnings Calendar:
Market Cap: $ 6,776,347
https://creativemedicaltechnology.com
Sec Filling | Patents | n/a employees

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company committed to improving patient lives in the areas of Immunology, Urology, Neurology and Orthopedics. Creative Medical Technology Holdings, Inc. is focused on regenerative medical solutions for unmet Immunological, Urological, Neurological and Orthopedic needs. The company has developed an extensive intellectual property portfolio utilizing stem cells and interrelated technologies for the treatment of multiple indications and commercialized complete patented and trademarked protocols for erectile dysfunction under the CaverStem® brand and the FemCelz® brand for the treatment of female sexual dysfunction. Its StemSpine® technology has undergone a pilot study and is prepared for commercialization of it’s autologous (patients own stem cells) program with the vision of progressing it’s patented allogenic (donor cells) program through FDA clinical trial. CELZ is also breaking new ground with its ImmCelz® technology for the treatment of multiple indications. Its team consists of leading physicians and scientists specializing in regenerative medicine. Its "science-first" approach to procedures ensures that all of its technology is proven to be both safe and effective.

treatment urea brands t-cell

add to watch list Paper trade email alert is off

Press-releases

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Published: 2023-12-20 (Crawled : 20:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| 11.59% | O: -1.07% H: 43.17% C: 1.08%
fda back granted clearance medical technology trial

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
Published: 2023-09-19 (Crawled : 14:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| 2.77% | O: 2.5% H: 0.83% C: -0.9%
celz-201 stemspine fda back treatment clearance medical technology trial

Creative Medical Technology Announces $2 Million Share Repurchase Program
Published: 2023-06-12 (Crawled : 12:00) - prnewswire.com
CELZ | $4.995 -3.94% -5.91% 19K

| 20.96% | O: -0.91% H: 11.02% C: 3.76%
repurchase medical program technology

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line
Published: 2023-05-18 (Crawled : 22:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| -21.21% | O: 6.06% H: 2.71% C: -15.41%
stemspine back positive cell medical technology results study

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study
Published: 2023-04-12 (Crawled : 18:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| 7.44% | O: 160.33% H: 5.56% C: -30.56%
positive medical technology diabetes results study

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| -18.75% | O: 1.56% H: 0.0% C: -6.18%
SYNH | $42.98 0.0% 7.4M

Health Services

| 8.23% | O: 0.03% H: 0.45% C: -1.01%
celz-201 medical technology trial diabetes international phase 1

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
Published: 2023-02-14 (Crawled : 16:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| -29.14% | O: 9.33% H: 4.7% C: 1.36%
stemspine year back

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| 29.84% | O: 19.85% H: 41.67% C: 4.17%
treatment fda clearance drug application technology diabetes therapy

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line
Published: 2022-10-20 (Crawled : 12:20) - prnewswire.com
CELZ | $4.995 -3.94% -5.91% 19K

| 33.33% | O: 5.08% H: 10.3% C: 0.39%
technology

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study
Published: 2022-09-26 (Crawled : 16:00) - biospace.com/
CELZ | $4.995 -3.94% -5.91% 19K

| -5.04% | O: -0.91% H: 5.97% C: -10.62%
stemspine technology positive publication study

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001477932-23-004914	4	2023-06-29	2023-06-28	Buy	P	200	12209
0001477932-23-004914	4	2023-06-29	2023-06-27	Buy	P	200	12009
0001477932-23-004914	4	2023-06-29	2023-06-27	Buy	P	300	11809
0001477932-23-004914	4	2023-06-29	2023-06-27	Buy	P	300	11509